Centessa Pharmaceuticals plc (NASDAQ:CNTA) Sees Large Increase in Short Interest

Centessa Pharmaceuticals plc (NASDAQ:CNTA) was the target of a significant growth in short interest in July. As of July 15th, there was short interest totalling 1,450,000 shares, a growth of 27.2% from the June 30th total of 1,140,000 shares. Based on an average daily volume of 246,600 shares, the short-interest ratio is currently 5.9 days. Approximately 2.1% of the company’s stock are sold short.

Centessa Pharmaceuticals Stock Up 0.7 %

CNTA stock traded up $0.07 on Tuesday, hitting $10.72. The company had a trading volume of 1,352 shares, compared to its average volume of 306,212. Centessa Pharmaceuticals has a 12-month low of $5.15 and a 12-month high of $12.45. The company has a current ratio of 10.37, a quick ratio of 10.37 and a debt-to-equity ratio of 0.36. The stock’s 50-day simple moving average is $9.14 and its 200 day simple moving average is $9.61.

Centessa Pharmaceuticals (NASDAQ:CNTA) last issued its earnings results on Monday, May 13th. The company reported ($0.38) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.41) by $0.03. On average, research analysts expect that Centessa Pharmaceuticals will post -1.62 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the stock. BMO Capital Markets reaffirmed an “outperform” rating and set a $15.00 target price on shares of Centessa Pharmaceuticals in a research note on Monday, April 1st. Oppenheimer assumed coverage on shares of Centessa Pharmaceuticals in a research note on Thursday, July 18th. They set an “outperform” rating and a $14.00 target price for the company. Finally, Morgan Stanley raised their price target on shares of Centessa Pharmaceuticals from $8.00 to $11.00 and gave the company an “equal weight” rating in a research report on Friday, June 21st. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat.com, Centessa Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $11.00.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. HighMark Wealth Management LLC purchased a new position in shares of Centessa Pharmaceuticals during the 2nd quarter worth $840,000. Lynx1 Capital Management LP purchased a new position in shares of Centessa Pharmaceuticals during the 1st quarter worth $197,000. Farallon Capital Management LLC purchased a new position in shares of Centessa Pharmaceuticals during the 1st quarter worth $4,192,000. Artal Group S.A. boosted its stake in shares of Centessa Pharmaceuticals by 39.5% during the 1st quarter. Artal Group S.A. now owns 1,412,500 shares of the company’s stock worth $15,961,000 after acquiring an additional 400,000 shares during the last quarter. Finally, First Light Asset Management LLC purchased a new position in shares of Centessa Pharmaceuticals during the 1st quarter worth $33,923,000. Hedge funds and other institutional investors own 82.01% of the company’s stock.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its pipeline products include SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of NT1 with potential expansion into other sleep disorders.